Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

por van Vollenhoven, Ronald F, Petri, Michelle A, Cervera, Ricard, Roth, David A, Ji, Beulah N, Kleoudis, Christi S, Zhong, Z John, Freimuth, William
Publicado 2012

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty‐Two–Week Randomized, Double‐Blind, Placebo‐Controlled Study

por Stohl, William, Schwarting, Andreas, Okada, Masato, Scheinberg, Morton, Doria, Andrea, Hammer, Anne E., Kleoudis, Christi, Groark, James, Bass, Damon, Fox, Norma Lynn, Roth, David, Gordon, David
Publicado 2017

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

por Bruce, Ian N, Furie, Richard A, Morand, Eric F, Manzi, Susan, Tanaka, Yoshiya, Kalunian, Kenneth C., Merrill, Joan T, Puzio, Patricia, Maho, Emmanuelle, Kleoudis, Christi, Albulescu, Marius, Hultquist, Micki, Tummala, Raj
Publicado 2022